Welcome to Angion Biomedica! We are a biopharmaceutical company dedicated to the discovery and development of novel therapeutics that save lives and improve the quality of life through modulation of the body's reparative and regenerative systems.

We provide therapeutic solutions for unmet medical needs in acute and chronic tissue, organ injury and fibrosis. Our discovery and development efforts have yielded a rich and diverse product pipeline comprising small molecule modulators of the HGF/c-Met pathway, inhibitors of PARP and blockers of the TGFβ1 receptor that are in advanced preclinical or clinical development.

• Angion receives IND approval from FDA to start clinical trials in liver fibrosis patients.
• Angion receives clearance from FDA to start clinical trials in patients with renal disease.
• Angion completes first-in-class HGF mimetic Phase IIA clinical trial.